Anti-Acid Drug Treatment Induces Changes in the Gut Microbiome Composition of Hemodialysis Patients
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Anti-acid drugs, proton pump inhibitor (PPI) and histamine-2 blocker (H2-blocker), are commonly prescribed to treat gastrointestinal disorders. These anti-acid drugs alter gut microbiota in the general population, but their effects are not known in hemodialysis patients. Hence, we investigated the microbiota composition in hemodialysis patients treated with PPIs or H2-blocker. Among 193 hemodialysis patients, we identified 32 H2-blocker users, 23 PPI users, and 138 no anti-acid drug subjects. Fecal samples were obtained to analyze the gut microbiome using 16S RNA amplicon sequencing. Differences in the microbial composition of the H2-blocker users, PPI users, and controls were assessed using linear discriminant analysis effect size and the random forest algorithm. The species richness or evenness (α-diversity) was similar among the three groups, whereas the inter-individual diversity (β-diversity) was different between H2-blocker users, PPI users, and controls. Hemodialysis patients treated with H2-blocker and PPIs had a higher microbial dysbiosis index than the controls, with a significant increase in the genera Provetella 2, Phascolarctobacterium, Christensenellaceae R-7 group, and Eubacterium oxidoreducens group in H2-blocker users, and Streptococcus and Veillonella in PPI users. In addition, compared to the H2-blocker users, there was a significant enrichment of the genera Streptococcus in PPI users, as confirmed by the random forest analysis and the confounder-adjusted regression model. In conclusion, PPIs significantly changed the gut microbiota composition in hemodialysis patients compared to H2-blocker users or controls. Importantly, the Streptococcus genus was significantly increased in PPI treatment. These findings caution against the overuse of PPIs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“PPIs, for instance, enrich Firmicutes and oral taxa like Streptococcus salivarius and Micrococcaceae, expand Veillonella and Enterocloster, and reduce overall diversity, a profile linked to Clostridioides difficile infection and adverse metabolic shifts.43,92–97”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [95]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106 · cited 1×
“The differential abundance analysis was also analyzed using DESeq2 methods [22].”
Metagenomic biomarker discovery and explanation
Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W. S., & Huttenhower, C. (2011) · Genome Biology · doi:10.1186/gb-2011-12-6-r60 · Cited by 16,192 · cited 1×
“The bacterial community difference between H2-blocker users, PPI users, and controls by the linear discriminant analysis (LDA) of effect size (LEfSe) analysis [19], heat tree method [20], hierarchical clustering heat map, and random forest method [21].”
MethodThe Human Intestinal Microbiome in Health and Disease
Lynch, S. V., & Pedersen, O. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1600266 · Cited by 3,637 · cited 1×
“Gut microbes have key roles in metabolic, nutritional, and physiological processes in the human body [39].”
BackgroundRandom Forest: A Classification and Regression Tool for Compound Classification and QSAR Modeling
Svetnik, V., Liaw, A., Tong, C., Culberson, J. C., Sheridan, R. P., & Feuston, B. P. (2003) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci034160g · Cited by 3,573 · cited 1×
“The bacterial community difference between H2-blocker users, PPI users, and controls by the linear discriminant analysis (LDA) of effect size (LEfSe) analysis [19], heat tree method [20], hierarchical clustering heat map, and random forest method [21].”
MethodThe Treatment-Naive Microbiome in New-Onset Crohn’s Disease
Gevers, D., Kugathasan, S., Denson, L. A., Vázquez-Baeza, Y., Van Treuren, W., Ren, B., Schwager, E., Knights, D., Song, S. J., Yassour, M., et al. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.02.005 · Cited by 3,220 · cited 4×
“However, HD patients taking H2-blocker or PPI had a higher MDI than controls (Figure 1B), with a significant difference in their microbiota composition (Figure 2).”
MethodInfluentialTransitions in bacterial communities along the 2000 km salinity gradient of the Baltic Sea
Herlemann, D. P. R., Labrenz, M., Jürgens, K., Bertilsson, S., Waniek, J. J., & Andersson, A. F. (2011) · The ISME Journal · doi:10.1038/ismej.2011.41 · Cited by 2,885 · cited 1×
“The amplicon library was constructed by amplifying the variable regions 3 and 4 (V3-V4) of the 16S rRNA gene using barcode-indexed PCR primers (341F and 805R) [16] and the 16S amplicons were sequenced (300 bp paired-end) by an Illumina MiSeq sequencer by Genomics BioScience (Taipei, Taiwan).”
MethodLozupone, C. A., Hamady, M., Kelley, S. T., & Knight, R. (2007) · Applied and Environmental Microbiology · doi:10.1128/aem.01996-06 · Cited by 2,656 · cited 1×
“, diversity in bacterial composition between samples) was estimated by computing the Bray–Curtis distance, Jensen–Shannon divergence, or Jaccard index and visualized through a principal coordinates analysis (PCoA) to evaluate the difference in bacterial communities between anti-acid drug users and controls [17].”
MethodDhariwal, A., Chong, J., Habib, S., King, I. L., Agellon, L. B., & Xia, J. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx295 · Cited by 1,885
Chong, J., Liu, P., Zhou, G., & Xia, J. (2020) · Nature Protocols · doi:10.1038/s41596-019-0264-1 · Cited by 1,702
Self-citationTax4Fun: predicting functional profiles from metagenomic 16S rRNA data
Aßhauer, K. P., Wemheuer, B., Daniel, R., & Meinicke, P. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv287 · Cited by 1,578 · cited 1×
“Predicted functional genes were aligned with the Kyoto Encyclopedia of Genes and Genomes (KEGG) database and annotated by KEGG orthology (KO) using the R “Tax4Fun” package [25].”
MethodProton pump inhibitors affect the gut microbiome
Imhann, F., Bonder, M. J., Vich Vila, A., Fu, J., Mujagic, Z., Vork, L., Tigchelaar, E. F., Jankipersadsing, S. A., Cenit, M. C., Harmsen, H. J. M., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-310376 · Cited by 1,371 · cited 3×
“The distinct microbial composition in H2-blocker users, PPI users, and controls was demonstrated, showing that, like in previous reports [10,14,15], PPI use was associated with an increased abundance of the genera Streptococcus and Veillonella.”
BackgroundResultChronic kidney disease alters intestinal microbial flora
Vaziri, N. D., Wong, J., Pahl, M., Piceno, Y. M., Yuan, J., DeSantis, T. Z., Ni, Z., Nguyen, T.-H., & Andersen, G. L. (2013) · Kidney International · doi:10.1038/ki.2012.345 · Cited by 1,164 · cited 1×
“There is a bidirectional causal effect relationship in patients with chronic kidney disease (CKD) and gut microbial changes [1].”
BackgroundCurrent Understanding of Dysbiosis in Disease in Human and Animal Models
DeGruttola, A. K., Low, D., Mizoguchi, A., & Mizoguchi, E. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000750 · Cited by 1,122 · cited 1×
“Changes in this microbial equilibrium, that is, dysbiosis, can promote many intestinal and extra-intestinal diseases [40,41].”
BackgroundComparative Analysis of Human Gut Microbiota by Barcoded Pyrosequencing
Andersson, A. F., Lindberg, M., Jakobsson, H., Bäckhed, F., Nyrén, P., & Engstrand, L. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002836 · Cited by 1,038 · cited 1×
“In our study, members of the genus Streptococcus, commensals of the human oral cavity, nasopharynx, and esophagus [30], in particular, S.”
BackgroundProton pump inhibitors alter the composition of the gut microbiota
Jackson, M. A., Goodrich, J. K., Maxan, M.-E., Freedberg, D. E., Abrams, J. A., Poole, A. C., Sutter, J. L., Welter, D., Ley, R. E., Bell, J. T., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-310861 · Cited by 895 · cited 2×
“Furthermore, the long-term reduction of gastric acid secretion by PPIs was suggested to decrease gut microbial richness, alter the composition of both gastric and intestinal microbiota, and increase oral bacteria and potentially pathogenic bacteria [10,11].”
BackgroundFreedberg, D. E., Kim, L. S., & Yang, Y.-X. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.031 · Cited by 891 · cited 1×
“However, long-term anti-acid drugs have been found to be associated with several adverse events, such as osteoporosis, fracture, hypomagnesemia, vitamin B12 deficiency, iron deficiency anemia, CKD, dementia, and pneumonia [5,6].”
BackgroundMetacoder: An R package for visualization and manipulation of community taxonomic diversity data
Foster, Z. S. L., Sharpton, T. J., & Grünwald, N. J. (2017) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1005404 · Cited by 825 · cited 1×
“The bacterial community difference between H2-blocker users, PPI users, and controls by the linear discriminant analysis (LDA) of effect size (LEfSe) analysis [19], heat tree method [20], hierarchical clustering heat map, and random forest method [21].”
MethodJackson, M. A., Verdi, S., Maxan, M.-E., Shin, C. M., Zierer, J., Bowyer, R. C. E., Martin, T., Williams, F. M. K., Menni, C., Bell, J. T., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05184-7 · Cited by 616 · cited 1×
“Moreover, commonly used medications are associated with distinct gut microbiota signatures [2].”
Complications of Proton Pump Inhibitor Therapy
Vaezi, M. F., Yang, Y.-X., & Howden, C. W. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.04.047 · Cited by 482 · cited 1×
“However, long-term anti-acid drugs have been found to be associated with several adverse events, such as osteoporosis, fracture, hypomagnesemia, vitamin B12 deficiency, iron deficiency anemia, CKD, dementia, and pneumonia [5,6].”
BackgroundBavishi, C., & DuPont, H. L. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04874.x · Cited by 480
Production of Gamma-Aminobutyric Acid from Lactic Acid Bacteria: A Systematic Review
Cui, Y., Miao, K., Niyaphorn, S., & Qu, X. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030995 · Cited by 451 · cited 1×
“Therefore, PPI’s effect on GABA biosynthesis may link bacteria’s intracellular pH value [35].”
BackgroundUse of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis
Eom, C.-S., Jeon, C. Y., Lim, J.-W., Cho, E.-G., Park, S. M., & Lee, K.-S. (2011) · Canadian Medical Association Journal · doi:10.1503/cmaj.092129 · Cited by 393 · cited 10×
“Furthermore, the long-term reduction of gastric acid secretion by PPIs was suggested to decrease gut microbial richness, alter the composition of both gastric and intestinal microbiota, and increase oral bacteria and potentially pathogenic bacteria [10,11].”
BackgroundInfluentialGut Microbiome Dysbiosis and Immunometabolism: New Frontiers for Treatment of Metabolic Diseases
Belizário, J. E., Faintuch, J., & Garay-Malpartida, M. (2018) · Mediators of Inflammation · doi:10.1155/2018/2037838 · Cited by 341
Freedberg, D. E., Toussaint, N. C., Chen, S. P., Ratner, A. J., Whittier, S., Wang, T. C., Wang, H. H., & Abrams, J. A. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.06.043 · Cited by 322 · cited 2×
“The distinct microbial composition in H2-blocker users, PPI users, and controls was demonstrated, showing that, like in previous reports [10,14,15], PPI use was associated with an increased abundance of the genera Streptococcus and Veillonella.”
BackgroundResultGut microbiome in chronic kidney disease: challenges and opportunities
Nallu, A., Sharma, S., Ramezani, A., Muralidharan, J., & Raj, D. (2017) · Translational Research · doi:10.1016/j.trsl.2016.04.007 · Cited by 255 · cited 2×
“In patients with kidney disease, the dysbiotic gut microbiome produced various uremic toxins and inflammation contributing to the complications [42,43].”
BackgroundProton Pump Inhibitors: Review of Emerging Concerns
Nehra, A. K., Alexander, J. A., Loftus, C. G., & Nehra, V. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.10.022 · Cited by 248 · cited 1×
“Among the medications, the acid-suppressive agents, such as histamine-2 blockers (H2-blocker) or proton pump inhibitors (PPIs), are generally well tolerated and commonly prescribed in patients with end-stage renal disease (ESRD) [3] as the first-choice treatment for acid-related disorders [4].”
BackgroundSafety of Proton Pump Inhibitor Exposure
Yang, Y., & Metz, D. C. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.08.023 · Cited by 219 · cited 1×
“Third, PPIs induce hormonal changes, including hypergastrinemia and hyperparathyroidism, which can alter the gastrointestinal bacterial milieu [32].”
BackgroundMechanisms and improvement of acid resistance in lactic acid bacteria
Wang, C., Cui, Y., & Qu, X. (2018) · Archives of Microbiology · doi:10.1007/s00203-017-1446-2 · Cited by 213 · cited 1×
“The proton pump is also included in the acid-resistance system of lactic acid bacteria [34].”
BackgroundProton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis
Hutchinson, C., Geissler, C. A., Powell, J. J., & Bomford, A. (2007) · Gut · doi:10.1136/gut.2006.108613 · Cited by 205 · cited 1×
“Studies reported that the PPI-mediated reduction of gastric acid causes a reduction in the absorption of dietary iron [37,38].”
BackgroundA comparison of the gut microbiome between long‐term users and non‐users of proton pump inhibitors
Clooney, A. G., Bernstein, C. N., Leslie, W. D., Vagianos, K., Sargent, M., Laserna‐Mendieta, E. J., Claesson, M. J., & Targownik, L. E. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13568 · Cited by 166
Microbiota intestinal en la enfermedad renal crónica
Cigarrán, S., Parra, E. G., & Cases, A. (2016) · Nefrología · doi:10.1016/j.nefro.2016.05.008 · Cited by 164 · cited 1×
“Thus, therapeutic interventions to restore intestinal dysbiosis was recognized as a potential therapeutic target in patients with kidney disease [42,44].”
BackgroundTakagi, T., Naito, Y., Inoue, R., Kashiwagi, S., Uchiyama, K., Mizushima, K., Tsuchiya, S., Okayama, T., Dohi, O., Yoshida, N., et al. (2018) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.17-78 · Cited by 121 · cited 2×
“The distinct microbial composition in H2-blocker users, PPI users, and controls was demonstrated, showing that, like in previous reports [10,14,15], PPI use was associated with an increased abundance of the genera Streptococcus and Veillonella.”
ResultMacke, L., Schulz, C., Koletzko, L., & Malfertheiner, P. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15604 · Cited by 118 · cited 1×
“Other PPI-associated taxa reported from a systematic review [27], such as the order Bacillales (e.”
BackgroundIntestinal Dysbiosis Secondary to Proton-Pump Inhibitor Use
Naito, Y., Kashiwagi, K., Takagi, T., Andoh, A., & Inoue, R. (2018) · Digestion · doi:10.1159/000481813 · Cited by 107 · cited 1×
“A meta-analysis found that PPI induced a shift in the Gram-positive bacteria Streptococcus and Enterococcus [28].”
Xu, H. B., Wang, H. D., Li, C. H., Ye, S., Dong, M. S., Xia, Q. J., Zhang, A. Q., Pan, K., Ge, X. L., & Dong, J. H. (2015) · Genetics and Molecular Research · doi:10.4238/2015.july.3.25 · Cited by 89 · cited 1×
“In addition, PPI also increases sepsis risk, spontaneous bacterial peritonitis, and enteric infections [47,48].”
BackgroundStadlbauer, V., Horvath, A., Ribitsch, W., Schmerböck, B., Schilcher, G., Lemesch, S., Stiegler, P., Rosenkranz, A. R., Fickert, P., & Leber, B. (2017) · Scientific Reports · doi:10.1038/s41598-017-15650-9 · Cited by 86 · cited 1×
“In patients with kidney disease, the dysbiotic gut microbiome produced various uremic toxins and inflammation contributing to the complications [42,43].”
BackgroundProton pump inhibitor therapy predisposes to community‐acquired Streptococcus pneumoniae pneumonia
de Jager, C. P. C., Wever, P. C., Gemen, E. F. A., van Oijen, M. G. H., van Gageldonk‐Lafeber, A. B., Siersema, P. D., Kusters, G. C. M., & Laheij, R. J. F. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12069 · Cited by 76 · cited 1×
“A significantly increased risk of community-acquired pneumonia has been observed with PPIs [45], specifically for Streptococcus-derived pneumonia [46].”
Backgroundvan der Loo, B., Bachschmid, M. M., Spitzer, V., Brey, L., Ullrich, V., & Lüscher, T. F. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00360-7 · Cited by 74 · cited 1×
“In addition, PPIs could markedly reduce the proportion of vitamin C in its biologically active antioxidant form of ascorbic acid [36] because of a marked and sustained rise in intragastric pH.”
BackgroundWhat are the effects of proton pump inhibitors on the small intestine?
Fujimori, S. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i22.6817 · Cited by 70 · cited 2×
“Second, the diminished gastric acid secretion and small intestinal dysmotility cause the small intestinal bacterial overgrowth of microaerophilic microorganisms such as Streptococcus, Staphylococcus, Escherichia, and Klebsiella and anaerobic bacteria such as Bacteroides, Lactobacillus, Veillonella, and Clostridium [31…”
ResultThe association of proton pump inhibitors and hypomagnesemia in the community setting
Markovits, N., Loebstein, R., Halkin, H., Bialik, M., Vesterman‐Landes, J., Lomnicky, J., & Kurnik, D. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.316 · Cited by 69 · cited 1×
“luminal contents, interfering with nutrient absorption, and changing the amount or location of bacterial food substrates [33].”
BackgroundThe Phosphate Binder Ferric Citrate Alters the Gut Microbiome in Rats with Chronic Kidney Disease
Lau, W. L., Vaziri, N. D., Nunes, A. C. F., Comeau, A., Langille, M. G. I., England, W., Khazaeli, M., Suematsu, Y., Phan, J. L., & Whiteson, K. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.251389 · Cited by 49 · cited 1×
“The microbial communities of HD patients contained higher amounts of Bacteroidetes and lowered Firmicutes levels, similar to CKD rat microbial communities [26].”
BackgroundProton Pump Inhibitor Usage and the Risk of Mortality in Hemodialysis Patients
de Francisco, A. L. M., Varas, J., Ramos, R., Merello, J. I., Canaud, B., Stuard, S., Pascual, J., Aljama, P., Aljama, P., Canaud, B., et al. (2017) · Kidney International Reports · doi:10.1016/j.ekir.2017.11.001 · Cited by 41
Gut Microbiota In Chronic Kidney Disease
Nalewajska, M., Przybyciński, J., Marchelek‐Myśliwiec, M., Dziedziejko, V., & Ciechanowski, K. (2019) · Postępy Mikrobiologii - Advancements of Microbiology · doi:10.21307/pm-2019.58.3.237 · Cited by 27
Okamoto, T., Hatakeyama, S., Hosogoe, S., Tanaka, Y., Imanishi, K., Takashima, T., Saitoh, F., Suzuki, T., & Οhyama, C. (2018) · PLoS ONE · doi:10.1371/journal.pone.0199160 · Cited by 21 · cited 1×
“In addition, PPIs have been associated with an increased risk of mortality [7], major adverse cardiovascular events [8], vascular calcification [9], and hip fracture [3] in patients with kidney disease.”
BackgroundVangala, C., Niu, J., Lenihan, C. R., Mitch, W. E., Navaneethan, S. D., & Winkelmayer, W. C. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02190218 · Cited by 21 · cited 3×
“Among the medications, the acid-suppressive agents, such as histamine-2 blockers (H2-blocker) or proton pump inhibitors (PPIs), are generally well tolerated and commonly prescribed in patients with end-stage renal disease (ESRD) [3] as the first-choice treatment for acid-related disorders [4].”
BackgroundA Proton Pump Inhibitor a Day Keeps the Iron Away
Handa, P., & Kowdley, K. V. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.09.007 · Cited by 9 · cited 1×
“Studies reported that the PPI-mediated reduction of gastric acid causes a reduction in the absorption of dietary iron [37,38].”
BackgroundZhou, S., Wang, S., Ma, Y., Tang, L., Shi, Y., Liang, B., Chen, Y., & Yu, K. (2016) · Hematology · doi:10.1080/10245332.2016.1142711 · Cited by 9 · cited 1×
“In addition, PPI also increases sepsis risk, spontaneous bacterial peritonitis, and enteric infections [47,48].”
BackgroundTsai, I., Lai, T., Shiao, C., Huang, T., Wang, C., Tsao, C.-H., Chen, L., Lin, Y., Chen, L., Wu, V., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1762 · Cited by 9 · cited 1×
“In addition, PPIs have been associated with an increased risk of mortality [7], major adverse cardiovascular events [8], vascular calcification [9], and hip fracture [3] in patients with kidney disease.”
BackgroundSelf-citationPassing the “Acid Test”: Do Proton Pump Inhibitors Affect the Composition of the Microbiome?
Dong, T. S., & Pisegna, J. R. (2018) · Digestive Diseases and Sciences · doi:10.1007/s10620-018-5273-3 · Cited by 5
Cited by
Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy
Thomas, A. M., Fidelle, M., Routy, B., Kroemer, G., Wargo, J. A., Segata, N., & Zitvogel, L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00785-8 · Cited by 141
Xia, B., Yang, M. G., Nguyen, L. H., He, Q., Zhen, J., Yu, Y., Di, M., Qin, X. S., Lu, K., Kuo, Z. C., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.08.005 · Cited by 94
Meta-analysis of the effects of proton pump inhibitors on the human gut microbiota
Zhang, J., Zhang, C., Zhang, Q., Yu, L., Chen, W., Xue, Y., & Zhai, Q. (2023) · BMC Microbiology · doi:10.1186/s12866-023-02895-w · Cited by 74
Interplay between gut microbiota, bone health and vascular calcification in chronic kidney disease
Rodrigues, F. G., Ormanji, M. S., Heilberg, I. P., Bakker, S. J. L., & de Borst, M. H. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13588 · Cited by 56
Potential effects of the most prescribed drugs on the microbiota-gut-brain-axis: A review
Garg, K., & Mohajeri, M. H. (2024) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2024.110883 · Cited by 34
“In addition, dysbiosis is observed in functional dyspepsia, with cirrhosis, haemodialysis, rheumatoid arthritis and cancer patients, who show specific increase in Streptococcus genus (Bajaj et al., 2018; Lin et al., 2021).”
Metadata
- Authors
- Lin, Y.-T., Lin, T.-Y., Hung, S.-C., Liu, P.-Y., Wu, P.-H., Chuang, Y.-S., Hung, W.-C., Chiu, Y.-W., Kuo, M.-C., & Wu, C.-Y.
- Affiliations
- Kaohsiung Medical University (TW)
- Tzu Chi University (TW)
- National Taiwan University (TW)
- Kaohsiung Medical University Chung-Ho Memorial Hospital (TW)
- National Health Research Institutes (TW)
- Corresponding author
- Wu, Ping-Hsun
- ORCID
- Venue
- Microorganisms
- Publisher
- MDPI AG
- Published
- 2021-01-30
- Volume
- 9
- Issue
- 2
- Pages
- 286
- ISSN
- 2076-2607 (ISSN-L)
- PMC
- PMC7910989
- OpenAlex
- W3129141123
- Cited by
- 22
- References
- 49
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 6 · 2023: 6 · 2022: 1 · 2021: 2
- FWCI
- 1.18
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Microorganisms (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministry of Science and Technology, Taiwan (MOST 106-2314-B-037-054, MOST 107-2314-B-037-104, and MOST 107-2314-B-037-098-MY3)
- Kaohsiung Medical University Hospital, Taiwan (KMUH105-5R15, KMUH106-6R17, KMUH106-6T03, KMUH107-7R16, KMUH107-7R78, KMUH108-8M11, and KMUH108-8R70)
- Kaohsiung Medical University, Taiwan (KMU-Q108024 and KMU-Q108027)
- NSYSU-KMU JOINT RESEARCH PROJECT (NSYSUKMU 105-I005 and NSYSUKMU 106-I005)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- proton pump inhibitors, H2 receptor antagonists, gut microbiota, hemodialysis patients, dysbiosis, Streptococcus, Phascolarctobacterium, Christensenellaceae, Veillonella, beta diversity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.